DRUG TRIAL CHANGES MOOTED
German authorities are considering changes to how drug trials are conducted because of a disastrous outcome in London last month. Six British volunteers became violently ill when they took a monoclonal antibody treatment designed and manufactured in Germany. The new rules may forbid simultaneous testing of high risk drugs and stipulate that the product be given to one volunteer at a time.
Originally the drug, TGN1412, was to have been tested in Berlin, but because British authorities gave the green light for the Phase 1 trial first, the contract research company Parexel, chose London. The drug was created by a small biotech in Bavaria started by scientists from W?rzberg University and was manufactured by one of Germany’s largest drug companies, Boehringer Ingelheim.
Several of the volunteers have been discharged from hospital, but one is still in a serious condition. Two have been telling their story to British newspapers and on television. The pain felt as though “a truck had been parked on my head”, 24-year-old Nav Modi told The Sun. He had planned to use his ?2,000 fee to buy a laptop after completing his MBA.
Creative commons
clinical trials
- How long can you put off seeing the doctor because of lockdowns? - December 3, 2021
- House of Lords debates assisted suicide—again - October 28, 2021
- Spanish government tries to restrict conscientious objection - October 28, 2021
More Stories
Mortality rates for American kids are rising for the first time in 50 years
US President Joe Biden is so concerned about the future of American children that he inserted a mandate for affordable...
Will Pope Francis be composted?
Will Pope Francis be composted instead of buried in St Peter’s Basilica in Rome with his predecessors? It’s unlikely. But...
The virtues and the vices of the outrageous
A Norwegian bioethicist, Anna Smajdor, recently set out a case for “Whole Body Gestational Donation” – using the wombs of...
More than 200 people have been treated with experimental CRISPR therapies
Scientists believe that CRISPR gene editing technologies will transform medicine. But how many people have been treated so far? According...
Asia-Pacific IVF market could reach US$46 billion by 2031
According to a market survey by Allied Market Research, IVF is booming in the Asia-Pacific region. The market size was...
Third global summit on human genome editing: Moving on after the He experiment
The much anticipated Third International Summit on Human Genome Editing was held in London earlier this month to explore the...